Vanguard Group Inc Actinium Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,571,764 shares of ATNM stock, worth $2.51 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,571,764
Previous 1,617,372
2.82%
Holding current value
$2.51 Million
Previous $2.04 Million
24.2%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ATNM
# of Institutions
72Shares Held
8.18MCall Options Held
51.9KPut Options Held
6.2K-
Black Rock Inc. New York, NY1.88MShares$3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA712KShares$1.14 Million0.0% of portfolio
-
State Street Corp Boston, MA645KShares$1.03 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA499KShares$798,8160.0% of portfolio
-
Ubs Group Ag396KShares$633,8170.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $40.3M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...